The invention relates to a capsule for releasing agents contained therein at defined points in a body, particularly useful for the examination of the digestive tract.
It is a generally known fact that a significant part of all drugs is taken in the form of tablets or capsules containing agents that can be absorbed in the digestive tract. With the exception of the stomach, for which the application of medicaments is well managed, the precise location of the absorption could not be adjusted until now. An inherent disadvantage resides in the fact that the passage speed through the intestine and the pH value in the intestine varies considerably for different persons and even for a particular individual depending upon his/her condition. Therefore, even especially prepared capsules used for medicaments, e.g. time controlled, enzyme controlled, pH value controlled or pressure controlled capsules, imply the risk that the agent may pass the target area without being absorbed in a sufficiently large quantity. But, conversely, if intentional overdoses are used, there will be the risk of unintended side effects.
In the past, a number of methods, arrangements and capsules have become known that were focused on the determination of the specific position of a medicament capsule in the intestine and, if the target position was reached, were implemented to release the agent via remote control; see Andrä, W. et al., A novel method for real-time magnetic marker monitoring in the gastrointestinal tract, Physics in Medicine and Biology 45: 3081-3093 (2000); Hemmati, A., The Site of Iron Absorption in the Gastrointestinal Tract, German Med. Mth., Vol. XIII: 569-573 (1968); DE 29 28 477 A1; Grönig, R., Computer-controlled drug release from small-sized dosage forms, Journal of Controlled Release 48: 185-193 (1997); U.S. Pat. No. 510,801 A; DE 19745 890 A1; U.S. Pat. No. 4,239,040 A; U.S. Pat. No. 5,279,607 A. Most of the capsules described in the aforementioned publications have at least one of the following disadvantages. First, they contain a hard cover. Thus, there is the risk that such capsules may get stuck on stenoses in the intestine and possibly have to be removed by operative surgery. According to the publication by Rösch, T et al., in Derzeitige klinische Indikationen der Kapsel-Endoskoopie (Current clinic indications of capsule endoskopy) in the German journal Zeitschrift für Gastroenterologie (Journal for gastroenterology) 40: 971-978 (2002), this danger can even exist if stenoses have not been registered during a previous x-ray examination. Additionally, the capsules mentioned include hard parts, such as metal springs, batteries and electronic components or circuits that can have a toxic effect if they contact the intestinal wall.
These two aforementioned disadvantages can be avoided by means of the intestine therapy capsule manufactured according to DE 197 45 890 A1 and, in the same way, by an already suggested capsule with a rotating ball, if suitable substances are used. But these solutions suggest a disadvantage that is due to the mechanism of release. The release is achieved by heating up a partial volume of the capsule (hereinafter referred to as heating element) in an alternate magnetic field by magnetic losses or by friction losses to such a degree that an organic substance melts or the opening of the capsule is activated in another way. Here, the intestine content or the intestinal wall, or the liquid agent is positioned in the direct vicinity of the heating element. The thermal conductivity of this environment is so high that the increased heating of the heating element causes the dissipation of an increased amount of heat into the environment that therefore does not contribute to the temperature rise of the heating element.
The maximally achievable rise in temperature is determined by the fact that the total power that is input by the alternating field is dissipated into the environment. According to the theory of thermal conduction, the maximally achievable rise in temperature is proportional to the input power and approximately reversely proportional to the thermal conductivity of the environment. The thermal conductivity of the environment for the capsules described is 0.2 W/(m-K) or higher. The thermal resistance between the heating element and the environment is on the order of 1 to 10 K/W. The selected input power of the alternate magnetic field must be sufficiently high to reach the desired maximum temperature despite the heat dissipation. The input power of the alternate magnetic field must not be as high as may be desired because, otherwise, an excessive heating of the patient can be caused by eddy current losses in the body tissue [Brezovich, I. A., Low frequency hyperthermia: capacitive And ferromagnetic thermoseed methods, Medical Physics Monographs 16: 82-111 (1988)].
It is therefore the object of the present invention to avoid the described disadvantages in an capsule design in accordance with the invention directed to preventing the capsule from getting stuck on stenoses while endowing the same with thermally acceptable characteristics and favorable properties from the point of view of energy.
The object of the present invention is achieved by a capsule for releasing at least one agent contained therein at defined positions in a body, which comprises capsule parts enclosing the capsule including at least one insulating capsule part, a material of which has a greater thermal resistance than an other of said capsule parts. At least one heating element at least partially surrounded by said at least one insulating capsule part is provided, wherein the capsule is openable by heating the at least one heating element under an effect of at least one alternating magnetic field. The capsule is dissolvable when entering in contact with a solving liquid. The thermal resistance of the capsule part(s) surrounding the heating elements(s) should be higher than the thermal resistance of the other capsule parts or of common capsules used for medicaments, at least by one order. The invention makes it possible that, on the one hand, all parts of the capsule consist of substances that disintegrate or dissolve when entering in contact with a liquid medium and, on the other hand, the capsule part designated as the heating element is surrounded by a cover that has a considerably greater thermal resistance than 10 K/W. The power required to reach the release temperature is reduced by adding a thermal insulation envelope. The heating generated under the influence of the alternate magnetic fields in at least one part of the capsule leads to a remote-controlled evaporation of an easily evaporating liquid disponed threrin. This liquid presses the agent (or several agents) out of the interior of the capsule, or it causes the capsule wall, which is comprised of parts, to burst. An advantageous embodiment of this invention contains a capsule part at least partially surrounding the heating element, which is closed against the agent by a wall, variable with respect to its position and/or its expansion.
In a preferred embodiment, at least one heating element that contains a magnetic powder, e.g. Fe3O4 (magnetite), is surrounded by a thermally insulating envelope. Said envelope can be double-walled, in which the walls consist essentially of water-soluble material, such as hard gelatin or sugar, and which are separated by a gas layer, e.g. air. As the whole capsule may only have a specific size to avoid difficulties when swallowing it, the thickness of this envelope is also reduced. Therefore, this thickness must be considered when comparing the thermal conductivity without and with this envelope. Ideally, the thermal resistance of the envelope is about 500 K/W, in relation to a normal medicament capsule of the same size of which the thermal resistance is about 10 K/W. Instead of the double-walled envelope it is also possible to use a porous envelope of water-soluble material with enclosed gas pockets. The thermal conductivity of such porous materials and the conductivity of air differ only slightly.
The present invention will now be described in more detail by way of the following schematic examples.
A thin layer (eg., film or foil) 19 of polyethylene, shellac or another suitable substance covering the whole capsule 10 protects the capsule 10 against decomposition in a water containing and/or enzyme containing environment, that is given, for example, in the intestinal tract. The opening 112 can also be arranged at another point of the capsule part 11. Instead of the double-walled part 12, it is also possible to use a component that contains gas pockets and is made of water-soluble material. Finally, the capsule 10 is neither bound to the embodiment shown in
In is noted that the dividing wall 213 that is movable in the capsule part 12 is not bound to the configuration shown in
The described invention demonstrates advantage in comparison to the state of the art. Due to the much greater thermal resistance of the insulation of part 12, the power of the alternate magnetic field supplied to the capsule 10 can be considerably less for the same intended maximum temperature, e.g. 78° C., than for the capsules without an insulation cover. Although the volume of the heating element becomes smaller due to the insulation, the required supplied power for the same maximum temperature is ideally less than 1% of the power that must be supplied for the capsule without thermal insulation. Another advantage is offered by the expandable bag 17 or a flexible and/or movable wall that closes the heating element 16 against the agent 14. Such approach avoids the use of pistons and similar elements made of hard material. When heating the magnetic powder above the temperature of ebullition of the liquid contained in the heating element, said liquid will evaporate and the agent will be discharged after a short period of time. Thus, the point of time and the location of the agent application are much better defined in this invention than in the methods and arrangements known heretofore. It is even possible to apply the agent subsequently in several portions if the supplied alternate field power is measured out appropriately. The construction of the capsule 10 has the effect that after the discharge of the agent 14, the water-containing intestinal liquid, for example, enters into the capsule 10 and decomposes the capsule parts 11, 12 or the hard gelatin stamp 21 from the inside. The other parts of the capsule (magnetic powder, polyethylene foil) can be easily ducted so that the remainder of the capsule do not get stuck on stenoses.
The individual features or any combination thereof described in the invention and the figures are inclusive of, but not limiting of, the invention, which is defined by the claims.
10 capsule
11, 12 (capsule) parts
13 membrane
14, 141, 142 agents
15, 151, 152 air, insulation material
16, 161, 162 heating elements
17 bag
18 coil
19 layer, foil
20 area
21 stamp
111,121 bent zones
112, 1121, 1122 openings
122 guide surfaces
131, 132 valves, plugs
171 folded structure
211 sealing and supporting elements
212 arrow
213, 214 flexible and/or movable dividing walls
215 fixed dividing wall
X-X axis
Number | Date | Country | Kind |
---|---|---|---|
DE 10 2004 034 35 | Jul 2004 | DE | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/DE05/01086 | 6/15/2005 | WO | 1/16/2007 |